Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19COVID-19의 잠재적인 치료를 위한 SARS-CoV-2 단백질에 대한 두 가지 말 제형의 개발 및 특성화Article Published on 2021-05-102022-09-01 Journal: Scientific Reports [Category] SARS, 진단, 치료법, 치료제, [키워드] alterations anti-RBD Anti-S1 anti-SARS-CoV-2 anti-viral antibody antibody Antibody therapy antivenom Antiviral agents Applied immunology bites and stings caprylic acid Clinical efficacy clinical trials convalescent plasma COVID-19 development ELISA equine evaluated exhibited Final horse Hyperimmune plasma immunization immunized Immunochemistry immunoreactivity Immunotherapy in vitro mixture N protein neutralizing capacity outbreak physicochemical polyclonal pool Potential treatment priming profile RBD reached Receptor binding domain recombinant proteins S1 protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 protein SEM tested therapy therapy for COVID-19 treatment for COVID-19 two group two groups Viral [DOI] 10.1038/s41598-021-89242-z PMC 바로가기 [Article Type] Article
Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients코로나19 환자의 호흡부전 치료제로 레닌-안지오텐신계 보호팔을 활성화하는 신약 개발Review Published on 2021-05-012022-09-11 Journal: Drug discovery today [Category] SARS, 신약개발, 치료법, [키워드] 20-hydroxyecdysone ACE inhibitors ACE2 activate acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 agonist agonists angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 Angiotensin receptor blockers Anti-inflammatory caused clinical picture coronavirus COVID-19 COVID-19 patient Developing drug enzyme global health Health Imbalance Impact IMPROVE induce pandemic Potential treatment proportion Protective RAS reached Rebalance receptor Renin renin-angiotensin system Respiratory failure SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severe pneumonia [DOI] 10.1016/j.drudis.2021.02.010 PMC 바로가기 [Article Type] Review
Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score MatchingMedicine Published on 2021-04-232022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 1:1 antibiotic baseline characteristics Clinical outcome comparison control group Coronavirus disease 2019 COVID-19 progression determine duration of symptom Efficacy evaluation enrolled evaluated Hospital stay matching median Mortality mortality rate non-severe patient Patient patients patients treated patients with COVID-19 Potential treatment Prevent progressed propensity score matching proportion reduce SARS-CoV-2 RNA score severe acute respiratory syndrome coronavirus 2 severe COVID-19 significantly shorter Standard therapy statistically significant difference therapy thymosin alpha 1 Thymosin-α1 Viral RNA shedding with COVID-19 [DOI] 10.3389/fmed.2021.664776 PMC 바로가기 [Article Type] Medicine
Successful Spinal Cord Stimulation for Necrotizing Raynaud’s Phenomenon in COVID-19 Affected Patient: The Nightmare Comes BackAnesthesiology Published on 2021-04-192022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome Anxiety back characterized condition CORD coronavirus COVID-19 distal effective endotheliopathy Evidence initial Interaction Ischemia Necrosis oxygen Pain patients peripheral ischemia peripheral tissues phenomenon Potential treatment raynaud phenomenon recent reducing reported SARS-CoV-2 SARS-COV-2 infection SCS selected spinal spinal cord stimulation Stimulation Stress Symptom syndrome systemic inflammatory temperature thrombotic event treated Treatment triggered Vascular vascular disease vascular pain vessels [DOI] 10.7759/cureus.14569 PMC 바로가기 [Article Type] Anesthesiology
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials무작위 시험의 국제 협력 메타 분석에서 COVID-19에서 히드록시클로로퀸과 클로로퀸의 사망률 결과Meta-Analysis Published on 2021-04-152022-09-10 Journal: Nature Communications [Category] MERS, SARS, 바이오마커, 임상, 치료법, [키워드] 95% CI 95% confidence interval all-cause mortality Analysis benefit bioRxiv children Chloroquine CIs clinical clinical trials Comorbidities COVID-19 COVID-19 patient COVID-19 patients COVID-19 research diagnostic Effect Effects eligible Epidemiology Evidence finding Generalizability High dose Hydroxychloroquine hydroxychloroquine/chloroquine include increased mortality International investigated investigator investigators medRxiv Meta-analysis Mortality Odds ratio Odds ratios outcome outpatients Patient patients Potential treatment Pragmatic pregnant women random-effects meta-analyses randomized clinical trial randomized trial RCT RCTs recovery recruitment registry Result survival total sample size Treatment Trial trials viral infection WHO WHO International Clinical Trials Registry Platform [DOI] 10.1038/s41467-021-22446-z PMC 바로가기 [Article Type] Meta-Analysis
Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomersArticle Published on 2021-04-132022-10-29 Journal: Scientific Reports [Category] COVID-19, MERS, SARS, [키워드] Analysis anti-malarial drug baseline biological samples clinical benefit clinical evaluation clinics COVID-19 develop development Diseases Drug discovery effective Efficacy evaluated HCQ HPLC Hydroxychloroquine isomer limit optical Potential treatment profile provide quantification Quantitative reported severe coronavirus disease Standard deviation tested Toxicity Treatment [DOI] 10.1038/s41598-021-87511-5 PMC 바로가기 [Article Type] Article
Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical TrialRandomized Controlled Trial Published on 2021-04-132022-10-05 Journal: JAMA [Category] SARS, 임상, [키워드] adverse event clinical clinical benefit clinically collected conducted Course COVID-19 database determine Effect enrolled follow-up period hazard ratio headache Health Hospitalized IMPROVE IQR Ivermectin ivermectin group laboratory-confirmed log-rank test median age median time Mild multiorgan failure outcome outcomes Patient per day Placebo Potential Potential treatment primary analysis population random Randomized randomized trial receive reported Resolution resolution of symptom resolution of symptoms resolved Serious Adverse Event significantly study participant study period Support Symptom symptomatic Symptoms the placebo group time Treatment Trial with mild disease women [DOI] 10.1001/jama.2021.3071 PMC 바로가기 [Article Type] Randomized Controlled Trial
GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid proteinGCG는 뉴클레오캡시드 단백질의 액상 응축을 방해하여 SARS-CoV-2 복제를 억제합니다.Article Published on 2021-04-092022-09-10 Journal: Nature Communications [Category] MERS, SARS, 변종, 유전자 메커니즘, 치료법, 치료제, [키워드] Amino acid amino acid substitutions binding coding sequence coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disrupt disrupting exhibit gallate GCG Genome genome variant genomes GISAID GISAID database greater green tea identify IFN inhibit interfere knowledge leads nucleocapsid nucleocapsid protein polymorphism polyphenol Potential treatment predicted Protein Protein aggregation reveal RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 replication the SARS-CoV-2 Treatment Trigger triggers undergo Viral viral genome virion assembly viruses [DOI] 10.1038/s41467-021-22297-8 PMC 바로가기 [Article Type] Article
RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial철회된 기사: COVID-19 관리에서 favipiravir 대 hydroxychloroquine의 안전성 및 효능: 무작위 대조 시험Randomized Controlled Trial Published on 2021-03-312022-08-13 Journal: Scientific Reports [Category] 임상, 치료법, 치료제, [키워드] Acute heart failure Acute myocarditis Ain Shams University Hospital Arm Assiut University Hospital average clinical trial Comorbidities comparable COVID-19 demographic characteristics Diagnosis died Drug discovery effective Efficacy enrolled Favipiravir followed by FVP heart failure Heartburn Hydroxychloroquine infected patients management Mild moderate Moderate COVID-19 myocarditis nausea negativity Open-label oral oseltamivir oseltamivir Patient PCR PCR negativity Phase 3 Potential treatment randomised controlled trial randomized-controlled recruited reported Safe Safety SARS-CoV-2 PCR transaminitis Treatment university Viral viral infections [DOI] 10.1038/s41598-021-85227-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibitionSARS-CoV-2 감염은 숙주 세포 대사를 다시 연결하고 잠재적으로 mTORC1 억제에 취약합니다Article Published on 2021-03-252022-09-12 Journal: Nature Communications [Category] SARS, 진단, [키워드] Activation Air-liquid interface Alter block carbon caused cell line cell lines change changes COVID-19 COVID-19 patient COVID-19 patients cultures determine Efficacy epithelial epithelial cell epithelial cells Evidence evidence of expression facilitate feasible Glucose Glutamine host cell host cell metabolism increase inhibitor kidney lung lung ALI cultures lung tissue mechanism Mechanisms of disease metabolism mTORC1 Mucosal immunology oxidative pandemic of COVID-19 patients Potential treatment potential treatments pyruvate reduce reduce viral replication Replication required SARS-CoV-2 SARS-COV-2 infection suppresse susceptible TCA cycle therapy TOR signalling Treatment understanding viral infection viral replication [DOI] 10.1038/s41467-021-22166-4 PMC 바로가기 [Article Type] Article